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BACKGROUND: Decision support interventions (DESIs)
provide a mechanism to translate comparative effective-
ness research results into clinical care so that patients are
able tomake informed decisions. Patient decision support
interventions for prostate-specific antigen (PSA) have
been shown to promote informed decision making and
reduce PSA testing in efficacy trials, but their impact in
real world settings is not clear.
OBJECTIVE: We performed an effectiveness trial of PSA
decision support interventions in primary care.
DESIGN: A randomized controlled trial of three distribu-
tion strategies was compared to a control.
PARTICIPANTS: Participants included 2,550men eligible
for PSA testing (76.6 % of the eligible population) and
2001 survey respondents (60.1 % survey response rate).
INTERVENTIONS: The intervention groups were: 1)
mailed the DESI in DVD format, 2) offered a shared med-
ical appointment (SMA) to view the DESI with other men
and discuss, and 3) both options.
MAIN MEASURES: We measured PSA testing identified
via electronic medical record at 12 months and DESI use
by self-report 4 months after the intervention mailing.
KEY RESULTS: We found no differences in PSA testing
across the three distribution strategies over a year-long
follow-up period: 21%, 24%, 22% in the DESI, SMA, and
combined group respectively, compared to 21 % in the
control group (p=0.51). Self-reported DESI use was low
across all strategies at 4months: 16% in themailedDESI
group, 6 % in the SMA group, and 15 % in the combined
group (p=< 0.0001).
CONCLUSIONS: Mailing PSA decision support interven-
tions or inviting men to shared medical appointments
unrelated to a primary care office visit do not appear to
promote informed decisionmaking, or change PSA testing
behavior.
KEY WORDS: cancer prevention; prostate cancer; medical decision
making; prostate-specific antigen; early detection of cancer.
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D ecision support interventions (DESIs) provide a mecha-nism to translate comparative effectiveness research re-
sults into clinical care, so that patients are able to make
informed decisions. In efficacy trials, DESIs have been shown
to increase knowledge, activate patients to participate in
shared decision making, resulting in decisions that are more
informed and consistent with patient values.1 These tools have
been developed for many medical decisions; however, pros-
tate cancer screening with prostate specific antigen (PSA) is a
decision where informed decision making has been strongly
endorsed.2–5
Patient DESIs for PSA screening have been shown to
promote informed decision making and reduce prostate-
specific antigen (PSA) screening in efficacy trials.6,7 However,
the evidence supporting the use of decision support comes
primarily from randomized controlled trials performed in ideal
conditions—ensuring exposure to the intervention—with se-
lect populations of research volunteers. Several well-
conducted studies of these PSA-DESIs are available but have
been limited, either because participation required active con-
sent,8 limiting generalizability, or the studies were performed
at single sites and not randomized.9,10 Several other studies
have explored using PSA DESIs in conjunction with counsel-
ing or shared medical appointments, but these have also been
limited by select samples.11,12 Therefore, little is known about
the effectiveness of PSA-DESIs in an unselected popu-
lation of men in Breal world^ primary care settings,
despite recommendations that they be used to facilitate
decisions about PSA screening.
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To address this gap, we conducted an effectiveness trial to
determine the impact of several distribution methods in two
primary care settings. We designed the trial to maximize reach
and generalizability, to mimic conditions in primary care
where distribution of PSA-DESIs has been recommended.
Specifically, we conducted a randomized controlled trial com-
paring three distribution methods (mailing the DESI, offering
a shared medical appointment for DESI viewing, or both
options) to a control group. We hypothesized that providing
men with access to PSA-DESIs would result in uptake of the
DESIs by men in the intervention groups and a decrease in
PSA screening, as has been found in some efficacy trials.1,7
We also hypothesized that the use of DESIs would differ by
distribution strategy; specifically, we hypothesized men of-
fered both options would be more likely to use the DESIs.
METHODS
Setting
The trial was conducted in two geographically diverse primary
care sites. Site one was in Northern California, with seven
primary care practices, and site two was an academic general
internal medicine practice in the southeast United States.
Study Population and Randomization
The study received approval from the Institutional Review
Boards of each institution. To assure that the sample reflected
men in primary care practices, we obtained a HIPAAwaiver to
identify eligible men using the electronic health record and to
analyze their PSA testing information from their medical
record unless they opted out of participation. Men were eligi-
ble for the study if they were (1) aged 50–75 years, (2) did not
have a prostate cancer diagnosis, (3) had not had a PSA test in
the past 10 months and, (4) had not seen their primary care
physician in the last 3 months.
Interventions
Approximately every 2 weeks during the intervention period
(February 2011 to December 2012), a list of men who met the
eligibility criteria was randomly selected from the pool of
eligible patients in the electronic medical records (EMRs).
Patients were mailed a letter describing the study and a
postage-paid opt-out card. The mailing included information
about why PSA testing is controversial, and recommendations
by professional organizations indicating that men should be
informed and decide whether they want to be tested. In addi-
tion to the letter, depending on their randomization group, men
also received: (1) a DESI in DVD format; (2) an invitation to
participate in a shared (group) medical appointment (SMA) to
watch and discuss the DESI with a mid-level healthcare pro-
vider and other patients; (3) both the DVD DESI and an
invitation to participate in a SMA or (4) no additional inter-
vention material. The PSA-DESI is 31 minutes long and was
developed by the Informed Medical Decisions Foundation. In
several controlled trials, the program has been found to be
balanced, increase knowledge and decrease desire for PSA
testing .12,13 The content describes tests to detect prostate
cancer, options for treatment if cancer is found, with informa-
tion about the associated benefits and risks, and that the
mortality benefit of treatment is uncertain.
Participant Survey 4 Months after Study Mailing
We surveyed men 4 months after the study materials were
mailed. We first sent a written survey to men who had not
opted out of the study, and if the survey was not returned
within 2 weeks, research staff called men to complete the
survey on the phone. Men not contacted within 8–10 weeks
were considered lost to follow-up but were still analyzed for
the PSA testing outcome, unless they had opted out of the
study.
Outcomes
The primary outcome was PSA screening at 12 months post-
mailing. PSA tests were identified from EMR data extraction.
Secondary outcomes determined by self-report during the
survey included DESI viewing and contact with providers
about PSA testing, PSA decision-specific knowledge,14 and
attitudes toward PSA testing.
Statistical Analyses
Statistical analyses consisted of both the intention-to-treat
and a priori secondary analyses. We used χ2 tests to
compare the group differences in PSA screening. Associa-
tions between the primary outcome and categorical vari-
ables were tested using Pearson’s χ2 and continuous var-
iables were tested using Student’s t-test. Secondary a priori
analyses were conducted on men who viewed the DESI.
In these analyses, survey non-respondents were classified
as having not viewed the DESI.
Covariates thought to be associated with PSA screening had
been selected based on prior work12,13,15 and clinical experi-
ence, and included race/ ethnicity (African American, Latino/
Hispanic, White, Asian/Pacific Islander, other) , age, sex,
marital status, education (less than high school, high school/
GED, some college, college graduate), income, insurance,
geographic site (site 1 or 2), and prior PSA screening (as
captured from the electronic medical record within 1 year prior
to enrollment). Covariates with a significance level (P value)
less than 0.05 were included in the multivariate logistic re-
gression model. Covariates for a logistic regression model for
DESI viewing were selected in the same manner. For both
outcomes (PSA screening and DESI viewing), the resulting
multivariate logistic regression that was used to estimate odd
ratios and 95 % confidence intervals (95 %CI), controlling for
group, study site, prior PSA screening, and insurance. (Please
see the Appendix for additional statistical details.)
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All analyses were executed using a two-sided α=0.05 and
all analyses used SAS software version 9.2. We based our
sample size calculation on the primary outcome, prostate
cancer screening. Because we planned to perform
pairwise comparisons using analysis of variance between
the four intervention groups, we used a Bonferroni
correction of 6 (effective two-sided alpha of 0.05/
6=0.0083) in our sample size calculation. We assumed
that the control group would have a screening rate of
55 % based on Behavioral Risk Factor Surveillance
System (BRFSS) screening rates at the time of the
proposal.16 We estimated that 650 men in each group
would provide 80 % power to detect a 10 % difference
in screening test completion.
RESULTS
In all, 4,028 men were randomly selected from the electronic
medical records, 701 men were ineligible and 777 men opted
out of the study (Fig. 1). Of the 2,550 participants who
remained eligible and did not opt out, 2001 completed a
questionnaire by mail or phone. This represents a 76.6 %
participation rate of eligible participants and a 60.1% response
rate for the survey.
Baseline Characteristics
Baseline characteristics were comparable across study groups
(Table 1). There were significant differences between the two
settings in terms of race/ethnicity, education, and income,
reflecting expected differences in the demographics of the
two primary care populations.
PSATesting. None of the distribution strategies demonstrated
a significant difference in PSA testing (Table 2): 21 %, 24 %,
and 22 % in the DESI, SMA, and combined groups, respec-
tively, compared to 21 % in the control group (p=0.51).
We found differences in PSA testing by site, but not across
the intervention groups at each site. For site one, the propor-
tion receiving PSA testing was 34 %, 37 %, 34 % in the DESI,
SMA, and combined groups, respectively, compared to 32 %
in the control group (p=0.66); for the second site, the propor-
tions were 9 % in the DESI group, 12 % in the SMA group,
10 % in the combined group, and 10 % in the control group
(p=0.57).
When we examined factors associated with PSA testing in
multivariate logistic regression model across the full sample,
we found that site, prior history of testing, and insurance were
significant. A participant from site 1 had 3.0 times the odds of
having a PSA test during the 12-month follow-up as a partic-
ipant at the second site (95 % CI: 2.3–3.8). Men who had a
prior history of PSA testing had 4.1 times the adjusted odds of
having a PSA test, compared to those who were screening
naïve (95 % CI: 3.1–5.4). Men who had Medicare or Medic-
aid, or HMO, or PPO/FFS had 3.6 (95 % CI: 1.8–7.4), 3.0
(95 % CI: 1.5–6.3), and 3.7 times (95 % CI: 1.8–7.5),
respectively, the adjusted odds of having a PSA test, compared
to those without insurance.
DESI Viewing. Among the three distribution strategies, DESI
viewing was low (Table 2). The combined strategy of offering
an invitation to a SMA in addition to a mailed DESI did not
lead to increased DESI viewing among participants (16 % in
DESI group vs. 15 % in the combined DESI+SMA group,
p=0.79). Further, few men attended the SMA groups [5.0 %
(33/656) in the SMA group and 3.6 % (23/636) in the com-
bined group].
Contact with Provider. At 4 months, 37 % (741/2,001) of the
cohort reported a primary care visit. There were no significant
differences between intervention groups for likelihood of
having a PCP visit [40 % DESI group (194/485)], 36 %
SMA group (185/510), 37 % combined group (180/485) vs.
37 % control group (182/489); p=0.65). Among men who
reported a visit, we found no significant differences in the
proportion of men who reported discussions with the doctor
about PSA testing during the visit [DESI 44 % (85/192), SMA
35 % (64/184), combined 37 % (66/177) vs. control 41 % (74/
182); p=0.26]. Additionally, few men in all groups attempted
to contact the doctor about PSA screening outside of a visit
(6 %), and there were no differences by intervention group
(DESI 7 %, SMA 8 %, combined 7 % vs. control 5 %;
p=0.45). Finally, among those who had a provider visit,
there was no difference in PSA testing [DESI 29 % (56/194),
SMA 32 % (60/185), combined 31 % (55/180) vs. control
group 26 % (48/182; p=0.63)].
DESI Efficacy. Compared to controls, DESI viewers were
significantly more likely to have a PSA test at 12 months
[DESI viewers 30 % (55/186) vs. the control group 21 %
(131/627); p=0.01]. Among men who reported an office
visit, DESI viewers were more likely than controls to engage
in discussions about PSA screening with their doctors [DESI
viewers 57 % (42/74) vs. control group 41 % (74/182);
p=0.02].
DESI viewing was associated with higher knowledge
scores (DESI viewers 76 %±24 % vs. 60 %±28 %; p<0.001)
and was also associated with less positive attitudes around
routine PSA screening for men their age [DESI viewers 54 %
(99/183) vs. control 65 % (323/495); p=0.008].
DISCUSSION
In this effectiveness trial, we found no differences in the
effect of DESI distribution strategies on PSA testing.
Use of the interventions across the intervention groups
was low, ranging from 6 to 16 %. Contrary to our
hypothesis, the combined SMA-DESI group did not
result in higher DESI uptake compared to the other
two intervention groups.
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Other studies have mailed DVDs,8,9,17,18 and some have
also encouraged group discussions regarding PSA screen-
ing.11,12 However, our study is larger than these previous
studies and was performed in a more generalizable population
in two settings in the US. Unlike our current findings, a much
smaller previous study by Frosch et al.12 demonstrated that a
group assigned to discussion (similar to our SMA) plus DESI
was less likely to have a PSA test completed compared to
usual care. However, this population was selected from an
ongoing screening program, and therefore does not likely
reflect a general primary care population. Similar to our find-
ings, Taylor and colleagues found no differences in PSA
testing by self-report at 13 months as a secondary outcome
in a large efficacy trial comparing web-based decision aid to
mailed print PSA DESIs.8 In Taylor et al.’s study, informed
consent was required, and the authors reported a participation
rate of less than 40 %. In our study, the participation rate was
over 75 % and the design allowed us to review PSA testing via
EMR for those who did not opt out.
Despite the fact that informed decision making has been
recommended regarding PSA testing by multiple professional
organizations,5,19,20 we found minimal impact of the interven-
tion despite the high reach of the mail out approach, primarily
because of the low uptake of the of DESIs. This low uptake
occurred despite significant media attention when the US
Preventive Services Task Force released new PSA recommen-
dations during the trial,21 where the media attention may have
increased interest in men learning more about PSA testing.
However, we found no difference in uptake before and after
the guidelines were released. The low use of DESIs is consis-
tent with previous non-randomized effectiveness studies that
mailed out colorectal cancer screening and PSA DVDs, where
uptake ranged from 10 to 36 %.9,17,18 Given the rigorous
design and the coincidental timing of our study with signifi-
cant media attention, mailing PSA-DESIs or using SMAs
unrelated to an upcoming visit do not appear to be effective
methods to promote informed decision making for PSA test-
ing. However, in a smaller study comparing an educational
pamphlet to a DVD, researchers have demonstrated uptake of
greater than 50 % when mailings of these materials were tied
to an upcoming office visit.22 So, uptake may have been
higher for this study if the mailings were tied to an upcoming
Figure 1 Randomization, eligibility, and participation
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office visit, but this approach would introduce a selection bias,
which our current design sought to avoid.
There are several other potential explanations for the low
uptake. First, we did not engage providers to promote DESI
use or train them in informed/shared decision making. Recent-
ly, DESIs have been developed to engage patients during the
office visit,23 which could potentially be more effective in
increasing uptake. However, a significant downside to this
approach is relying on providers to bring up the topic, rather
than having a systematic approach. Further, competing prior-
ities may limit the reach of this approach, and thus decrease its
overall impact.24 Additionally, the letter sent with the inter-
vention was not endorsed by the providers, and this may have
also decreased the likelihood of patients using the DESI.
In contrast to some efficacy trials that demonstrated a de-
crease in PSA use with DESI, we actually found that partici-
pants who reported using the DESI were more likely to obtain
a PSA test compared with controls, despite having higher
knowledge scores and a less positive impression of PSA
screening. The inconsistency of our findings with many effi-
cacy trials6,7 where DESI viewing is assured, suggests that
participants in efficacy trials who consent to participate may
be different than men in our effectiveness study, which did not
require opt-in consent. It also suggests that those who elected
to use the DESI may differ from those who chose not to use it.
The self-selected men who used the DESI may be more
Table 1 Baseline Participant Characteristics, by Site and Intervention Group
Combined Sites (n=2,550)
Both sites Site 1 Site 2 p value DESI SMA DESI+SMA Control p value
(n=2550) (n=1258) (n=1292) (n=631) (n=656) (n=636) (n=627)
Age, a mean (SD), y 59.0 (6.5) 58.3 (6.3) 59.7 (6.6) < 0.001 59 (6.5) 58.6 (6.6) 59.3 (6.5) 59.2 (6.3) 0.27
Race,b No. (%)
White 1765 (72) 901 (77) 864 (67) < 0.001 437 (71) 446 (71) 435 (71) 447 (74) 0.80
Black 360 (15) 26 (2) 334 (26) 80 (13) 97 (15) 101 (17) 82 (14)
Asian 194 (8) 176 (15) 18 (1) 57 (9) 52 (8) 42 (7) 43 (7)
Hispanic 65 (3) 54 (5) 11 (1) 19 (3) 14 (2) 16 (3) 16 (3)
Other 78 (3) 18 (2) 60 (5) 20 (3) 20 (3) 18 (3) 20 (3)
Missing 88 (4) 83 (7) 5 (< 1) 18 (3) 27 (4) 24 (4) 19 (3)
Education,c No. (%)
Less than highschool 177 (9) 9 (1) 168 (17) < 0.001 53 (11) 34 (7) 51 (11) 39 (8) 0.35
Highschool or GED 227 (12) 33 (4) 193 (19) 52 (11) 70 (14) 54 (12) 51 (10)
Some college 272 (14) 109 (12) 163 (16) 61 (13) 79 (16) 67 (14) 65 (13)
College 384 (20) 244 (26) 140 (14) 89 (19) 98 (19) 98 (21) 99 (20)
Some graduate school
or higher
894 (46) 538 (58) 356 (35) 226 (47) 228 (45) 209 (44) 231 (48)
Missing 596 (23) 325 (26) 271 (21) 150 (24) 147 (22) 157 (25) 142 (23)
Insurance,a No. (%)
PPO or fee-for-service 1212 (48) 745 (59) 467 (36) < 0.001 311 (49) 309 (47) 284 (45) 308 (49) 0.74
HMO 403 (16) 308 (25) 95 (7) 85 (14) 109 (17) 106 (17) 103 (16)
Medicare 538 (21) 169 (13) 369 (29) 136 (22) 133 (20) 144 (23) 125 (20)
Medicaid 89 (3) 6 (< 1) 83 (6) 22 (4) 19 (3) 27 (4) 21 (3)
Dual Medicare/Medicaid 65 (3) 1 (< 1) 64 (5) 13 (2) 18 (3) 20 (3) 14 (2)
No insurance 243 (10) 29 (2) 214 (17) 64 (10) 68 (10) 55 (9) 56 (9)
Income,c No. (%)
Less than $25,000 320 (20) 18 (2) 302 (35) < 0.001 82 (21) 81 (19) 82 (21) 75 (18) 0.92
$25,001 to $50,000 170 (10) 47 (6) 123 (14) 42 (11) 43 (10) 39 (10) 46 (11)
$50,001 to $99,999 270 (17) 113 (15) 157 (18) 64 (16) 76 (18) 57 (14) 73 (18)
Over $100,000 861 (53) 583 (77) 278 (32) 208 (53) 221 (53) 219 (55) 213 (52)
Missing 929 (36) 497 (40) 432 (33) 235 (37) 235 (36) 239 (38) 220 (35)
Employed,c No. (%)
Yes 1219 (62) 716 (77) 503 (49) < 0.001 301 (62) 324 (64) 286 (60) 308 (63) 0.62
No 743 (38) 219 (23) 524 (51) 183 (38) 186 (37) 193 (40) 181 (37)
Missing 588 (23) 323 (26) 265 (21) 147 (23) 146 (22) 157 (25) 138 (22)
Married,c No. (%)
Yes 1389 (70) 738 (79) 651 (63) < 0.001 337 (70) 358 (70) 338 (70) 356 (72) 0.79
No 584 (30) 199 (21) 385 (37) 147 (30) 155 (30) 145 (30) 137 (28)
Missing 577 (23) 321 (26) 256 (20) 147 (23) 143 (22) 153 (24) 134 (21)
Prior PSA testing,b No. (%) 238 (9) 148 (12) 90 (7) < 0.001 61 (10) 52 (8) 66 (10) 59 (9) 0.25
Survey Responders, No. (%) 2001 (78) 949 (75) 1052 (81) < 0.001 491 (78) 518 (79) 491 (77) 501 (80) 0.65
aData source: Electronic Medical Record
bData source: Electronic Medical Record and Patient Surveys
cData source: Patient Surveys
Table 2 Primary and secondary outcomes data by intervention
group
DESI SMA DESI+SMA Control
PSA testing at 12
months, No. (%)a
134 (21) 158 (24) 139 (22) 131 (21)
DESI viewing at 4
months, No. (%)b
78 (16) 33 (6) 75 (15) N/A
aWhole baseline sample: DESI n=631, SMA n=656, DESI+SMA n=
636, Control n=627
bSample among participants who completed the follow-up survey: DESI
n=491, SMA n=518, DESI+SMA n=491
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engaged with PSA testing and have higher baseline knowl-
edge. Our results suggest effectiveness trials are important to
determine the potential uptake and impact of DESIs in more
generalizable samples before recommendations are made to
encourage them as a standard of care in clinical practice.25
Our study has several important limitations. First, we relied
on men to contact their providers and set up a visit. Although
at 4 months, a significant proportion had been seen, our results
may have been different if we had tied mailing of DESIs to a
scheduled visit. Next, although our study was designed to
maximize generalizability, men who opted out of the study
or did not respond to the survey may be different than those
who did participate. However, it is important to note that a
strength of the study was that our study design allowed us to
determine PSA testing for the survey non-respondents who
did not opt-out of study participation. We have found in
previous work that men who do not respond to surveys are
very unlikely to have used decision support interventions.17
Finally, although we had a high participation rate (76 %) and
survey response rate (60 %), the proportion of men who chose
to use the DESI was small and self-selected. Our results
demonstrate that effectiveness trials can be useful to determine
uptake of DESIs in real world practice, as effects identified in
highly controlled efficacy trials may not replicate in larger
effectiveness trials. Consequently, both efficacy and effective-
ness studies are needed to determine the impact of DESIs in
clinical practice.
In conclusion, we found no differences in the impact of
DESI distribution strategies on PSA testing 12 months after
wemailed studymaterials to men eligible for PSA testing. Use
of the interventions across the intervention groups was low.
Mailing PSA decision support interventions or inviting men to
shared medical appointments unrelated to a primary care
office visit does not appear to promote informed decision
making for PSA testing or change PSA testing behavior.
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